|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities
Datamonitor, July 2006, Pages: 131
Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion.
However, Pfizers follow-on Lyrica (pregabalin), Lillys Cymbalta (duloxetine) and Endo/Elans Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.
Scope of this title:
- Detailed analysis of key brands, with sales and volume forecasts to 2014 for the neuropathic pain indication alone
- Assessment of current and future opportunities and threats in the neuropathic pain market across the seven major pharmaceutical markets
- Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
- Lifecycle management case studies show how previously successful strategies should be applied in todays market
Highlights of this title:
- After a brief slump in 2005, the neuropathic pain market is forecast to grow to $5.5 billion by 2015, led by Lyrica and Cymbalta. Pfizers commitment to neuropathic pain and Lillys targeted approach are both effective strategies that can be utilized by all new entrants.
- The presence of generic gabapentin has introduced strong cost competition in the market. Setting a competitive price point for a new product is vital as healthcare payers continue to push for lower drug prices and generic prescribing although innovation is rewarded with a premium price and a high level of reimbursement in most countries.
The current concerns surrounding the use of NSAIDs and opioids will be beneficial to neuropathic pain drug companies as physicians seek alternative analgesics for their patients. However, if they are to realize the full potential of the market, companies need to focus on expanding the patient potential by supporting physician education programs.
Reasons to order your copy:
- Quantify the future size of the neuropathic pain market in each of the seven major markets
- Understand key product differentiating factors that provide commercial advantages over existing therapies
- Compare market penetration and brand positioning strategies to those successfully employed by Pfizer, Endo, and Eli Lilly
Customers who bought this item also bought
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Peripheral Neuropathy and Neuropathic Pain
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Disease and Therapy Review: Neuropathic Pain
Neuropathic Pain Insight - Life Beyond Gabapentin
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
U.S. Neuropathic Pain Medications Markets
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
US Cancer Pain Report
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
Pain Therapeutics - Drugs, Markets and Companies
|
|
|
|
